MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Pathologically documented NSCLC Stage IA2, IA3, IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC. 2) Molecular testing results from CLIA-certified laboratories and showing at least one of the following abnormalities (ALK gene rearrangement, ROS1 gene rearrangement, NTRK1/2/3 gene rearrangement, BRAF V600 mutation).

You may not be eligible for this study if the following are true:

  • 1) NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease. 2) Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.